149 related articles for article (PubMed ID: 24697532)
1. Not too big, not too small: a goldilocks approach to sample size selection.
Broglio KR; Connor JT; Berry SM
J Biopharm Stat; 2014; 24(3):685-705. PubMed ID: 24697532
[TBL] [Abstract][Full Text] [Related]
2. Modified Goldilocks Design with strict type I error control in confirmatory clinical trials.
Zhan T; Zhang H; Hartford A; Mukhopadhyay S
J Biopharm Stat; 2020 Sep; 30(5):821-833. PubMed ID: 32297825
[TBL] [Abstract][Full Text] [Related]
3. Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma.
Tan SB; Chung YF; Tai BC; Cheung YB; Machin D
Control Clin Trials; 2003 Apr; 24(2):110-21. PubMed ID: 12689733
[TBL] [Abstract][Full Text] [Related]
4. Adaptive increase in sample size when interim results are promising: a practical guide with examples.
Mehta CR; Pocock SJ
Stat Med; 2011 Dec; 30(28):3267-84. PubMed ID: 22105690
[TBL] [Abstract][Full Text] [Related]
5. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
Cotterill A; Whitehead J
Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
7. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
[TBL] [Abstract][Full Text] [Related]
8. Group Sequential Design for Randomized Phase III Trials under the Weibull Model.
Wu J; Xiong X
J Biopharm Stat; 2015; 25(6):1190-205. PubMed ID: 25322440
[TBL] [Abstract][Full Text] [Related]
9. Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect.
Zhang YY; Ting N
J Biopharm Stat; 2018; 28(6):1119-1142. PubMed ID: 29513608
[TBL] [Abstract][Full Text] [Related]
10. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
11. Sample size re-estimation in a breast cancer trial.
Hade EM; Jarjoura D; Lai Wei
Clin Trials; 2010 Jun; 7(3):219-26. PubMed ID: 20392786
[TBL] [Abstract][Full Text] [Related]
12. Update on the NSABP and ACOSOG breast cancer sentinel node trials.
White RL; Wilke LG
Am Surg; 2004 May; 70(5):420-4. PubMed ID: 15156950
[TBL] [Abstract][Full Text] [Related]
13. Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.
Ibrahim JG; Chen MH; Xia HA; Liu T
Biometrics; 2012 Jun; 68(2):578-86. PubMed ID: 21955084
[TBL] [Abstract][Full Text] [Related]
14. Power and sample size for randomized phase III survival trials under the Weibull model.
Wu J
J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
[TBL] [Abstract][Full Text] [Related]
15. Biomarker threshold adaptive designs for survival endpoints.
Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
[TBL] [Abstract][Full Text] [Related]
16. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
Huang B; Talukder E; Han L; Kuan PF
J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
[TBL] [Abstract][Full Text] [Related]
17. Designing exploratory cancer trials using change in tumour size as primary endpoint.
Jaki T; André V; Su TL; Whitehead J
Stat Med; 2013 Jul; 32(15):2544-54. PubMed ID: 23280944
[TBL] [Abstract][Full Text] [Related]
18. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
Potthoff RF; Halabi S
Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
[TBL] [Abstract][Full Text] [Related]
19. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
Sugimoto T; Sozu T; Hamasaki T; Evans SR
Biostatistics; 2013 Jul; 14(3):409-21. PubMed ID: 23307913
[TBL] [Abstract][Full Text] [Related]
20. Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.
Jiang W; Wick JA; He J; Mahnken JD; Mayo MS
J Biopharm Stat; 2018; 28(5):824-839. PubMed ID: 29172970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
